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Aim: Although there has been an improvement in the hardware and software of the 
PET/MRI system, the development of the nanoprobes exploiting the simultaneous 
acquisition of the bimodal data is still under investigation. Moreover, few studies on 
biocompatible and clinically relevant probes are available. This work presents a core-
shell polymeric nanocarrier with improved relaxometric properties for simultaneous 
PET/MRI acquisitions. Materials & methods: Core-shell nanoparticles entrapping the 
Gd-DTPA and 18F-FDG are obtained by a complex coacervation. Results & discussion: 
The boosting of r1 of the entrapped Gd-DTPA up to five-times compared with ‘free Gd-
DTPA’, is confirmed by the PET/MRI scan. The sorption of 18F-FDG into the nanoparticles 
is studied and designed to be integrated downstream for the production of the tracer.
First draft submitted: 31 March 2017; Accepted for publication: 3 July 2017; Published 
online: 17 August 2017
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Nowadays, the combination of several imag-
ing modalities is used to increase the diagnos-
tic accuracy. Furthermore, the integration of 
the imaging modalities enabling the simulta-
neous acquisition of the different data could 
have a huge impact in the early diagnosis of 
various pathologies as neurodegeneration dis-
eases [1–8] and, therefore, in the clinical man-
agement of cognitive decline in early stage. 
In this context a pivotal role is represented by 
the hybrid PET/MRI [9]; the development of 
integrated PET/MRI started in 1997 with the 
aim to acquire simultaneously both modali-
ties combining their diagnostic contribution 
in a single high-resolution image [9]. Among 
several other advantages, the guarantee of 
having, for example, in a single image PET/
MRI a high anatomical detail and the infor-
mation on the metabolic processes associated 
with a disease not only leads to saving time 
and money but also gives the opportunity to 
make an early detection [10] and so to improve 
the effectiveness of the treatments [11]. Cur-
rently, magnetic resonance imaging and posi-
tron emission tomography are used separately 
and, only later, the two obtained images are 
superimposed on a unique diagnostic image. 
This implies a high risk of artifacts and the 
reduction of image resolution due to partial 
volume effects [12]. So, simultaneously PET/
MRI allows for both spatial and temporal 
correlation of the signals, creating opportu-
nities impossible to realize using sequentially 
acquired data [13]. The features of this new 
technology may be particularly appealing to 
applications in neuro science [7,13] and trans-
lational neurologic and psychiatric research 
[14], considering that MRI represents the 
first-line diagnostic imaging modality for 
numerous indications and that a significant 
number of specific PET tracers are available 
today to assess functional and molecular 
processes [15]. Nowadays, even though there 
are different commercial contrast agents and 
radiotracers, there is not a single probe that 
can be used for the simultaneous PET/MRI 
acquisition and the only way to exploit this 
technique is limited to the administration of 
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a risky cocktail of tracers [16]. Thanks to nanotechnolo-
gies, the design of new probes that provide the delivery 
of drugs and the combination of different molecular 
targeting is possible [17,18]. The development of an 
efficient and reliable PET/MR dual imaging probe is 
essential to actualize the PET/MR instrument’s pow-
erful application. Therefore, a dual probe allows an 
actual simultaneous acquisition and the co-localization 
of the two contrast agents and guarantees a temporal 
and spatial correlation of the two imaging modali-
ties. In vivo, the probe concentration that is, in gen-
eral, unknown, will change with time and may vary in 
diseased versus normal tissue. Using a bimodal PET/
MR probe, it has proven suitable to use PET for esti-
mating the overall concentration and the MR signal 
to determine the molar relaxivity of the agent, giving 
an accurate estimation of its specific biochemical or 
 physiologic target [19].
In this perspective, several efforts are made to pres-
ent multimodal probes for PET/MRI [20–24]. However, 
most of them are mainly based on the bioconjuga-
tion of the tracers to a carrier inducing the chemical 
modification of the molecules as approved for clini-
cal use by the US FDA [25,26] or entrap the diagnos-
tic compounds using not completely biocompatible 
materials [18,22,27,28]. Lee et al. [29] in 2008 presented 
a study in which arginine-glycine-aspartic (RGD) 
was conjugated to iron oxide NPs to develop a PET/
MRI probe for the detection of tumor integrin α
v
β
3
. 
Hwang et al. [30] in 2010, presented a review in which 
is reported state of the art about the development of 
new nanoprobe for PET/MRI acquisitions. In 2010, 
Zhu et al. [31] presented a new probe for PET/MRI 
formed by Mn-doped Fe
2
O
4
 (MnMEIO) with serum 
albumin conjugated with 124I. In 2011, a different 
probe for the multimodal imaging PET/MRI was pre-
sented by Uppal et al. [32]; this probe was created com-
bining Gd and 64Cu to evaluate fibrin imaging effect 
on rats. Yang et al. [33] demonstrated a drug delivery 
function for tumor application combining a tracer for 
MRI with a 64Cu and a drug (doxorubicin) conjugating 
them to SPIONs. In 2013, de Rosales [16] described the 
use of cocktails of imaging agents and bimodal agents 
to acquire information by PET/MRI technique, and 
he presented a probe (SPIONs) conjugated with 64Cu. 
An important characteristic of the presented literature 
studies is the use of radiopharmaceuticals which have 
a very high half-life and are not utilized in the clinical 
practice for their higher radioactive power.
Recently, we have developed an efficient way based 
on a modified complex coacervation and double cross-
linking reaction to produce hybrid core shell nanopar-
ticles (HyCoS NPs) with improved relaxometric prop-
erties and able to increase the relaxivity of the clinically 
relevant Gadolinium-based Contrast Agents up to five-
times without their chemical modification [34]. Here, 
the same HyCoS probe is presented, and its stability to 
a protocol of sorption of the fluorodeoxyglucose (18F-
FDG) is reported to be used as a tracer for integrated 
PET/MRI acquisitions. The radiopharmaceutical 
compound 18F-FDG is selected together with the Gd-
DTPA because they are the most commonly used in 
clinical practice for different kinds of diseases, poten-
tially enabling the easy translation of our designed 
probe in clinical practice.
Materials
Chitosan (Ch) low molecular weight; divinyl sulfone 
(DVS) 118.15 g/mol; sodium tripolyphosphate (TPP) 
367.86 g/mol; glacial acetic acid molecular weight 
60.05; ethanol (EtOH) molecular weight 46.07; Gd-
DTPA molecular weight 547.57; mineral oil 0.84 g/ml 
at 25°C; Span80 molecular weight 274.43; 1.005 g/
ml at 20°C are purchased by Sigma-Aldrich®, while 
hyaluronic acid (HA) 850 kDa parenteral grade is by 
Hyasis. MilliQ water is for all experiments. 18F-FDG 
(0.014 mg/ml) is synthesized and provided by IRCCS 
SDN of Naples.
Methods
Preparation of HyCoS NPs & their collection
As reported in a previous work, Vecchione et al. [34], 
HyCoS-NPs are produced through a complex coacerva-
tion process to obtain a core-shell architecture. Briefly, 
the HyCoS NPs are composed of a Chitosan core and 
a shell of HA. First of all, a w/o emulsion is prepared 
to obtain the core template. A total of 50 ml of a solu-
tion of mineral oil at 1% v/v Span80 is homogenized at 
7000 r.p.m. for 5 min. Then, an acetic acid (AcOH) solu-
tion (34.93 mM) at 1% w/v Ch and 1% w/v Gd-DTPA 
is added to the previous oil solution and homogenized 
for 20 min at 7000 rpm to obtain a w/o nanoemulsion. 
Consequently, a water solution at 30% w/v of TPP and 
0.1% w/v of HA is added to the previous emulsion and 
homogenized at 7000 rpm for other 30 min. Then, the 
emulsion is kept under continuous stirring overnight at 
300 rpm. NPs are then collected and purified to achieve 
a concentration from 3 to 5 mg/ml.
Characterization of HyCoS NPs
A field emission scanning electron microscope (FE-
SEM) by Zeiss transmission electron microscope 
(TEM) by FEI® in DRY, CRYO and tomography 
(TOMO) modes, are used to characterize the system 
morphologically. The SEM observations are made by 
collecting NPs on an ISOPORE membrane of 100 nm 
pore size. NPs are coated with 7 nm Au or Pt/Pd prior 
observation. The TEM analyses are conducted both in 
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Figure 1. Image of the specific phantom utilized to 
perform PET/MRI acquisition of hybrid core shell 
nanoparticles. The low volume glass burettes are filled 
with a selected sample at a specific concentration.
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DRY, CRYO and TOMO modes. In the DRY mode, 
20–40 μl of NPs are collected on a Formvar/Carbon 
200 mesh Cu, Agar. In CRYO mode, the samples are 
prepared using VITROBOT FEI coating Lacey Car-
bon film 200 mesh Cu Agar with 3 μl of NPs suspen-
sion under vitrification conditions of blotting time 1 s, 
humidity upper than 70% and temperature 20°C.
Synthesis of 18F-FDG
The radiotracer 18F-FDG is directly produced and 
used in the laboratories of the Diagnostic Center 
IRCCS SDN located in Naples. The chemical form 
of the 18F is [18F] fluoride ion, and it is produced by 
a cyclotron. Once the bombardment is complete, the 
radioactive solution containing the [18F] fluoride ion 
is transferred from the target to the chemistry process-
ing module where the reaction with the glucose for the 
formation of 18F-FDG occurs. Usually, a whole batch 
of 18F-FDG is dedicated to the testing of the NPs for 
each  experiment.
Protocol of absorption of 18F-FDG into HyCoS 
NPs loading Gd-DTPA
Absorption of decayed 18F-FDG
Protocol of absorption is preliminarily assessed by 
using decayed 18F-FDG at the IIT@CRIB Laborato-
ries. During this preliminary test, different parameters 
of sorption have been studied (volume ratio and time 
of contact between HyCoS NPs and FDG, stirring 
rate regarding rpm and vacuum pressure to perform 
ultrafiltration, etc.). After ultrafiltration and purifica-
tion steps, mass spectrometry (Agilent Technologies 
6530 Accurate-Mass Q-TOF LC/MS, USA) is used 
to measure the amount of decayed 18F-FDG loaded 
into the NPs. Furthermore, a release profile in phos-
phate-buffered saline of the NPs is studied by dialy-
sis. A total of 100 μl of the phosphate-buffered saline 
washing phase are collected every 10 min up to 12 h 
and replaced with fresh medium. The release profile is 
assessed by mass spectroscopy.
Absorption of radioactive 18F-FDG
The protocol of absorption of the radioactive tracer 
is directly conducted at the Radiopharmaceutical 
Department of the Diagnostic Center IRCSS SDN 
in Naples. Here, 100–500 μl of a solution 18F-FDG 
at 0.014 mg/ml and about 60 μCi/ml (t
0
) are added 
at different ratio to 100–500 μl of Gd-loaded NPs at 
a concentration of 1–5 mg/ml. The suspension is kept 
under continuous shaking for 5–10 or 20 min. This 
procedure is repeated at least four-times for at least four 
batches to achieve the required clinical administration 
dosage. Later, 1–3 ml of milliQ water are added to all 
the batches, and put under vacuum to perform ultrafil-
tration (30 s) through an adapted Concentrator Corn-
ing Disk (SPIN-X UF 30 kDa of 20 ml by SIGMA) 
enabling the controlled separation of not adsorbed 
radiotracer from the HyCoS NPs. Both the solution 
of water and the residual 18F-FDG, and the suspension 
of NPs are then collected in different tubes to measure 
their activities.
Simultaneous PET/MRI acquisition
After the protocol of sorption, the radioactive HyCoS 
NPs are collected and injected into each fillable sphere 
(inner diameters: 10 mm (A), 13 mm (B), 17 mm (C), 
22 mm (D), 28 and 37 mm) of a specific NEMA 
2012/IEC NEMA IEC Body Phantom (Figure 1); 
the phantom is placed at the isocenter of the PET/
MR field of view to perform simultaneous PET/MRI 
acquisition. The eluates of the related samples are 
also measured to assess the efficacy of the sorption. 
The images of radiotracer distribution, as well as MR 
T1-weighted sequence of bimodal contrast agent, were 
 simultaneously obtained by a PET/MRI scan.
In vitro MRI
Relaxation times of the Gd-loaded NPs are measured 
on a Bruker Minispec (mq 60) bench-top relaxome-
ter operating at 60 MHz for protons (magnetic field 
strength: 1.41 T). The acquisitions are performed at 
37°C. Before each measurement, the sample is placed 
into the nuclear magnetic resonance probe for about 
15 min for thermal equilibration. Longitudinal relax-
ation times, T
1
, is determined by both saturation (SR) 
and inversion recovery pulse sequences. Relaxivity 
values, r
1
, are calculated from the slope of the regres-
2226 Nanomedicine (Lond.) (2017) 12(18)
Figure 2. Morphological characterization. (A) SEM image of HyCoS NPs and (B) TEM image of core-shell 
HyCoS NPs. 
HyCoS NP: Hybrid core shell nanoparticle; SEM: Scanning electron microscope; TEM: Transmission electron 
microscope.
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sion line of 1/T
1
 [s-1] versus concentration [mM] with 
a least-squares method using Origin Pro 9.1 SRO soft-
ware (OriginLab Corporation, MA, USA). For the 
correct evaluation of the r
1
, Gd concentration of the 
NPs’ suspension is ranged between 0 and 100 μM to 
evaluate r
1
 avoiding the contribution of the T
2
 effects.
Results
The morphology of the HyCos NPs is characterized 
by SEM and TEM microscopy. In the following fig-
ure (Figure 2) are reported an SEM image and a TEM 
image of the NPs. Figure 2A highlights the spherical 
NPs while the Figure 2B shows the core-shell architec-
ture of the designed NPs.
The size of the NPs will play an important role in 
the biodistribution of the carries and in the accumula-
tion at a different time and different organs. However, 
currently, the selection of an appropriate architecture 
is able to deliver more than one tracer simultaneously, 
and eventually being a theranostic tool is the first step 
for the design of an effective multimodal probe.
Evaluation of the encapsulation efficiency of 
the decayed18F-FDG absorbed by NPs & their 
stability
A calibration line of glucose (range 0–0.014 mg/ml) 
used for the evaluation of the concentration of decayed 
18F-FDG by mass spectroscopy is shown.
After the contact and the purification protocols, a 
decayed 18F-FDG concentration of 0.00325 mg/ml is 
measured on the flow-through collected at the bottom 
of the flask. The difference between the residual prod-
uct and the initial amount of used 18F-FDG is reported 
in Table 1 and shows the quantity absorbed into the 
NPs.
Protocol of sorption
In the design of a process that should be integrated 
into an industrial and certificated quality system, cur-
rently in use in radiopharmaceutical laboratories for 
the development of a new multimodal probe, the first 
endeavor was to integrate the production of polymeric 
NPs with the synthesis of 18F-FDG. Indeed, the start-
ing idea was to encapsulate the glucose during the 
manufacturing process of the NPs and to perform, 
later, directly in the hot cell, the substitution of the 
oxygen with the 18F within the NPs. Unfortunately, 
the synthesis of 18F-FDG (Figure 3), such as the oth-
ers radiopharmaceutical tracers, is conducted at a 
temperature profile (104°C) not suitable for polymeric 
materials, causing the instability of the NPs. Further-
more, beyond the difficulties related to the stability 
of the NPs, even the quality controls of the 18F-FDG 
were compromised by this procedure while our aim is 
Table 1. Mass spectrometry: measures are made on eluate after a purification step of the particles.
NPs (μl) FDG 0.014 mg/ml 
(μl)
Initial amount of 
FDG (mg/ml) 
Destruction of the 
integrity of the NPs
Residual amount 
of FDG (mg/ml)
Difference (mg/
ml)
Sorption (%)
500 100 26.283E-13 Yes ND ND ND
500 10 26.283E-13 No 1.02715E-13 1.60115E-13 61
The results show a sorption of about 60% of the FDG after the contact of 10 min with the NPs.
FDG: Fludeoxyglucose; ND: Not determined; NP: Nanoparticle.
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Figure 3. Acquired profile of pressure and temperature during the 18F-FDG synthesis.
Figure 4. Morphological characterization of nanoparticles by field emission scanning electron microscope. 
Nanoparticles with Gd-DTPA after the sorption step performed with 18F-FDG decayed at 0.014 mg/ml.
Product: 18F-FDG, Process: FDG 1 (NaOH), Batch No.: 151118d, Operator: Admin, Start of Synthesis: 18.11.2015 07:10:08, Page 1/1  
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to improve the diagnostic without the chemical modi-
fication of the approved compounds. In this perspec-
tive, the production of a polymeric NP in the hot cells 
is not effective and extremely expensive. The second 
strategy we have carried out regards the combination 
of the 18F-FDG with the polymeric NPs by absorption 
of the radiotracer. In details, after their production, 
HyCoS NPs are subjected to freeze-drying to remove 
the excess water before keeping in contact the materi-
als as described in the Materials and Methods sections. 
An experimental campaign was conducted to estimate 
the conditions of sorption regarding the preservation 
of the shape of the NPs and encapsulation efficiency of 
the 18F-FDG. The optimal conditions are obtained by 
adding 100 μl of a solution 18F-FDG, at 0.014 mg/ml, 
at 60 μCi/ml (t
0
), to 500 μl of NPs. NPs’ suspension 
used for the sorption had a concentration of 1 mg/ml, 
a Gd concentration of 150 μM, a T
1
 = 300 ± 20 ms (T
1
 
equal to 750 μM of unloaded Gd-DTPA). Formed sus-
pension is kept under continuous shaking for 10 min. 
Later, 1 ml of milliQ water is added to all the batches, 
and put under vacuum to perform ultrafiltration.
Figure 4 reported an SEM image of NPs after the 
protocol of sorption with decayed 18F-FDG. The image 
clearly shows that the NPs maintain their shape after 
the protocol of absorption if it is performed at the 
2228 Nanomedicine (Lond.) (2017) 12(18)
Figure 5. Simultaneous PET/MRI acquisition: on the left: the MR scan; in the middle: PET/MR fusion; on the 
right: only PET observation.
Figure 6. In vitro MRI. Longitudinal relaxation rate as a function of (Gd-DTPA) concentration for: Gd-DTPA in 
distilled water at different concentrations (lower line); HyCoS NPs loaded with Gd-DTPA at different concentration 
(upper line); Linear regression is performed for each system, and related equations are showed. 
Gd-DTPA: Gadopentetic acid; HyCoS NP: Hybrid core shell nanoparticle.
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selected optimal conditions. At these conditions, the 
improved relaxometric properties of the loaded Gd-
DTPA are also preserved and the release of the radio-
tracers is detected only after 8 h.
In vitro simultaneous PET/MRI acquisition
Figure 5 shows the images resulting from the simulta-
neous PET/MR acquisition. The co-registration PET/
MRI (Figure 5, middle) of the signals on the samples do 
not present interference, enabling the measurements of 
a T
1
 equal to 300 ms (Figure 5, right A) and 600 ms 
(Figure 5, right B) and the PET in a range between 1.87 
(Figure 5, middle A) and 3.32 μCi (Figure 5, middle B), 
90 min after the synthesis of 18F-FDG (60 μCi/ml). 
The analysis of the radioactivity performed on the elu-
ates (Figure 5, right C & D) showed an activity of about 
6 μCi at the same time point (Figure 5, middle C & D). 
The time point for the measurement is selected tak-
ing into account the half-life of the radiotracer (about 
1 h). Results show that the amount of radiotracers 
absorbed by the HyCoS NPs is sufficient to obtain a 
human administration dosage. Furthermore, MRI 
analysis in samples at different concentration is 
reported in Figure 6. The slope of the line related to 
the linear regression represents the relaxivity r
1
 of the 
contrast agents. The plot shows a relaxivity r
1
 equal to 
4 for the commercial ‘free Gd-DTPA’ and to 21 for 
the HyCoS NPs entrapping the Gd-DTPA. Equation 
assessed a boosted relaxivity r
1
, on an MRI 3 Tesla, 
of about five-times compared with the free Gd-DTPA 
(Figure 6) even after the protocol of sorption. As pre-
viously reported, the concentration of the Gd-loaded 
NPs is ranged between 0 and 100 μM to avoid artifacts 
due to T
2
 effects.
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Figure 7. Graphical representation of future perspectives of hybrid core shell nanoparticles for integrated PET/MRI. 
FDG: Fludeoxyglucose; Gd-DTPA: Gadopentetic acid.
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Discussion
The proposed protocol could be integrated at the 
downstream of the synthesis of 18F-FDG. Indeed, 
the radiotracer can be entrapped into the NPs taking 
advantages by the positive charge of the chitosan core 
which can attract the radiotracer and control its release 
by sorption. Furthermore, using the method described 
in this chapter, it is possible to combine the designed 
nanovectors directly with the radiotracers, making 
the product available as a ready-to-use compound in 
the clinical practice. The sorption of the radiotracer 
within the NPs might be mainly due to the concentra-
tion gradient obtained by freeze drying between the 
external and the internal phases. However, the entrap-
ment of the radiotracer should probably be attributed 
to the positive charge of the chitosan scorekeeping the 
radiopharmaceutical compound (negatively charged) 
trapped in the polymer mesh. Future in vivo studies 
will assess the stability and the biodistribution of the 
NPs. Indeed, it is important to point out that when the 
tracers are entrapped within NPs, it will follow their 
biodistribution. In details, the radiotracer will not fol-
low the traditional metabolic pathway of the glucose 
but a new one dictated by the body clearance and 
interaction of the NPs. The protocol used enables pre-
paring an injectable suspension usable for simultane-
ous acquisitions PET/MRI without altering the chem-
ical nature of the molecules as approved by the FDA. 
In addition, the boosted relaxometric properties of the 
HyCoS NPs are also preserved, providing a probe with 
improved efficacy (Figures 5 & 6). The results show an 
enhancement in r
1
 of about five-times compared with 
the free Gd-DTPA, due to the presence of the mixed 
hydrophobic-hydrophilic hydrogels [35].
Furthermore, it is important to point out that the 
formulation of the HyCoS NPs respects the amount of 
radiotracer, the metal chelates concentration and the 
acquisition window currently in clinical use. It repre-
sents a significant and unique result, paving the way to 
a new class of completely biocompatible probes with 
improved performances that could add notable devel-
opment to the diagnostic field and the nanomedicine 
in general, with an effective exploitation of simultane-
ous hybrid imaging (Figure 7).
Conclusion
In conclusion, the HyCos NPs, encapsulated with Gd-
DTPA for MRI in a previous work, have been dried 
to be able to absorb 18F-FDG. A precise control of the 
components and the process parameters for the proto-
col of sorption was introduced to entrap efficiently 18F-
FDG for simultaneous PET/MRI applications without 
weakening the stability of the NPs and the release of 
the compounds. Indeed, using the proposed protocol, 
the HyCoS NPs preserve a boosting of the MRI signal 
and can absorb a detectable dosage of a radiotracer if 
opportunely treated.
The in vitro results performed on a PET/MRI scan 
have shown that the nanovectors improve the relaxo-
metric properties and preserve the radioactivity with-
out any chemical modification of the FDA-approved 
molecules. Furthermore, both the MR and the PET 
signals simultaneously acquired are not influenced by 
the presence of the polymer carrier.
Future development of this project will be the study 
of the biodistribution of the multimodal nanovectors 
to evaluate the stability of the complex and its biodis-
tribution.
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Summary points
•	 This work aims to design and develop new polymeric nanovectors for simultaneous PET/MRI acquisitions.
•	 The Gd-DTPA and the fluorodeoxyglucose (18F-FDG) are chosen respectively as a contrast agent for MRI and a 
radiotracer for PET imaging.
•	 The nanoparticles (NPs) are obtained by a modified complex coacervation process.
•	 The sorption protocol of the 18F-FDG by the NPs is specifically designed to entrap the tracer itself in the NPs 
downstream the production process of the 18F-FDG.
•	 In vitro PET/MRI analysis is made to evaluate the activity of the radiotracer absorbed by the NPs and the MR 
signal.
•	 Both the co-registred signals are simultaneously visible, and the PET signal is not negatively influenced by the 
presence of the polymer nanovector.
•	 The boosted relaxometric properties of the hybrid core shell NPs are also preserved improving the probe 
efficacy.
•	 The results show an enhancement in r1 of five-times compared with the free Gd-DTPA.
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